HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.74 USD | -0.66% |
|
-3.18% | +9.68% |
| Feb. 11 | Deutsche Bank Initiates Coverage on Harmony Biosciences With Buy Rating, $55 Price Target | MT |
| Feb. 03 | BofA Adjusts Price Target on Harmony Biosciences to $31 From $32 | MT |
Company Valuation: Harmony Biosciences Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,057 | 2,493 | 3,268 | 1,892 | 2,152 | 2,152 | - |
| Change | - | 21.23% | 31.09% | -42.12% | 13.77% | 0% | - |
| Enterprise Value (EV) 1 | 2,022 | 2,449 | 3,214 | 1,759 | 1,857 | 1,581 | 1,203 |
| Change | - | 21.1% | 31.25% | -45.28% | 5.58% | -14.87% | -23.89% |
| P/E ratio | -14.6x | 73.5x | 18.6x | 15.2x | 16x | 11.5x | 8.49x |
| PBR | - | - | - | - | 3.36x | 2.42x | 1.77x |
| PEG | - | -1x | 0x | -0.5x | 1.5x | 0.3x | 0.2x |
| Capitalization / Revenue | 12.9x | 8.16x | 7.46x | 3.25x | 3.01x | 2.55x | 2.07x |
| EV / Revenue | 12.7x | 8.02x | 7.34x | 3.02x | 2.6x | 1.87x | 1.16x |
| EV / EBITDA | 74.2x | 23x | 22.4x | 8.13x | 8.26x | 5.03x | 2.98x |
| EV / EBIT | 119x | 28x | 26.7x | 9.16x | 9.08x | 5.98x | 3.24x |
| EV / FCF | -677x | 24.9x | 22.3x | 8.03x | 8.63x | 7.51x | 4.16x |
| FCF Yield | -0.15% | 4.01% | 4.49% | 12.5% | 11.6% | 13.3% | 24.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.48 | 0.58 | 2.97 | 2.13 | 2.352 | 3.294 | 4.446 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 159.7 | 305.4 | 437.9 | 582 | 714.7 | 843.3 | 1,039 |
| EBITDA 1 | 27.26 | 106.4 | 143.6 | 216.4 | 224.7 | 314.4 | 404.4 |
| EBIT 1 | 16.99 | 87.53 | 120.2 | 192 | 204.6 | 264.2 | 371 |
| Net income 1 | -63.85 | 34.6 | 181.5 | 128.9 | 149 | 204.1 | 274.4 |
| Net Debt 1 | -34.38 | -44.32 | -54.14 | -133.1 | -295.4 | -571.6 | -949.2 |
| Reference price 2 | 36.15 | 42.64 | 55.10 | 32.30 | 37.74 | 37.74 | 37.74 |
| Nbr of stocks (in thousands) | 56,889 | 58,472 | 59,318 | 58,572 | 57,031 | 57,031 | - |
| Announcement Date | 3/25/21 | 2/28/22 | 2/21/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 16.05x | 2.6x | 8.26x | -.--% | 2.15B | ||
| 70.27x | 17.77x | 49.64x | 0.6% | 779B | ||
| 22.55x | 4.36x | 12.73x | 3.05% | 376B | ||
| 21.88x | 7.73x | 15.11x | 2.3% | 370B | ||
| 43.55x | 7.1x | 16.36x | 3.25% | 339B | ||
| 15.26x | 3.73x | 9.23x | 3.45% | 254B | ||
| 27.08x | 4.62x | 14.58x | 2.15% | 224B | ||
| 12.35x | 3.77x | 9.06x | 3.55% | 219B | ||
| 16.67x | 4.21x | 10.18x | 3.56% | 212B | ||
| 32.49x | 6.29x | 11.05x | 3.04% | 159B | ||
| Average | 27.81x | 6.22x | 15.62x | percentage-no-prefix | 293.37B | |
| Weighted average by Cap. | 36.62x | 8.68x | 22.54x | percentage-no-prefix |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- HRMY Stock
- Valuation Harmony Biosciences Holdings, Inc.